RxDoctor Payments Data

David Choi, DO

Interventional Cardiology · Fort Wayne, INNPI 1285864702

Payments from drug & device makers

$3,537in general payments, 2019–2025

Across 93 payments — averaging $38.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$1K
  • Angiodynamics, Inc.$659
  • Abbott$198
  • Cook Medical LLC$137
  • Endologix LLC$133
  • Penumbra, Inc.$125
  • plus $963 from 21 others

What the payments were for

  • Food & beverage$3,10488%
  • Other$43312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,537 in reported general payments places this provider in the 25th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$165,701
Medicare patients
752
Services billed
1,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$195,342
XareltoRivaroxaban55$64,632
EntrestoSacubitril/Valsartan45$61,577
Repatha SureclickEvolocumab49$44,375
BrilintaTicagrelor18$12,883
Ranolazine ErRanolazine29$4,267
Metoprolol Succinate315$4,166
Ezetimibe182$3,740
Atorvastatin Calcium444$3,327
Carvedilol480$3,145
Midodrine Hcl28$2,976
Diltiazem 24hr Er (Cd)Diltiazem Hcl85$2,487
ClopidogrelClopidogrel Bisulfate258$2,239
Losartan Potassium224$1,836
Potassium Chloride92$1,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$11$64,63255 claims
NovartisEntresto$76$61,57745 claims
AstraZenecaBrilinta$88$12,88318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →